Lerochol (lerodalcibep-liga) Coverage Criteria
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0299 alerts
Get alerted when Policy CC-0299 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and coverage of Lerochol, a monthly subcutaneous PCSK9 inhibitor used with diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It applies to providers requesting initial or continuation therapy and includes clinical criteria, step therapy, quantity limits, and billing codes.
The policy history reports updated indication wording and LDL threshold criteria.
The policy history reports updates to the step-therapy tables.
HCPCS NOC J3490 was removed from the policy coding list.
ICD-10-CM diabetes mellitus code ranges E10.10-E10.A2, E11.00-E11.A, and E13.00-E13.9 were added.
The policy history reports addition of step therapy and step-therapy tables.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.